



I hereby Certify that this Correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on September 29, 2006

Alicia Falkenbach

Name

Alicia Falkenbach

Signature

September 29, 2006

Date of Signature

IPW

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Ansorge, et al.

Filed: March 6, 2006

Serial No.: 10/520,014

For: Use of Alanyl Aminopeptidase Inhibitors and Pharmaceutical Compositions Containing Said Inhibitors

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Applicant wishes to make of record the following references under the provisions of 37 CFR §1.97.

References Cited

Please see attached Form PTO/SB/08A for list of PCT patent applications, foreign patent applications and publications. Legible copies of all applications and publications listed are enclosed.

The person making this statement is the patent attorney who signs below on the basis of the information supplied by the inventors, and as the attorney associated with the filing and prosecution of this application (37 CFR 1.56(a)).


Respectfully submitted,

By:

John D. Lopinski, Reg. No. 50,846

HODGSON RUSS LLP  
One M & T Plaza, Suite 2000  
Buffalo, New York 14203-2391  
Dated: September 29, 2006

Please type a plus sign inside this box



FD/5B/08A(05/03)

Approved for use through 05/31/2003, OMB 0651-0031

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

|                        |                |
|------------------------|----------------|
| Application Number     | 10/520,014     |
| Filing Date            | March 6, 2006  |
| First Named Inventor   | Ansorge et al. |
| Art Unit               |                |
| Examiner Name          |                |
| Attorney Docket Number | 013183.00044   |

Sheet 1 of 2

## **U.S. PATENT DOCUMENTS**

| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Document Number                          | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines<br>Where Relevant<br>Passages or Relevant<br>Figures Appear |
|-----------------------|--------------------------|------------------------------------------|--------------------------------|----------------------------------------------------|-----------------------------------------------------------------------------------|
|                       |                          | Number-Kind Code <sup>2</sup> (if known) |                                |                                                    |                                                                                   |
|                       |                          | US-                                      |                                |                                                    |                                                                                   |
|                       |                          | US-                                      |                                |                                                    |                                                                                   |
|                       |                          | US-                                      |                                |                                                    |                                                                                   |
|                       |                          | US-                                      |                                |                                                    |                                                                                   |
|                       |                          | US-                                      |                                |                                                    |                                                                                   |
|                       |                          | US-                                      |                                |                                                    |                                                                                   |
|                       |                          | US-                                      |                                |                                                    |                                                                                   |
|                       |                          | US-                                      |                                |                                                    |                                                                                   |
|                       |                          | US-                                      |                                |                                                    |                                                                                   |
|                       |                          | US-                                      |                                |                                                    |                                                                                   |
|                       |                          | US-                                      |                                |                                                    |                                                                                   |
|                       |                          | US-                                      |                                |                                                    |                                                                                   |
|                       |                          | US-                                      |                                |                                                    |                                                                                   |
|                       |                          | US-                                      |                                |                                                    |                                                                                   |

## **FOREIGN PATENT DOCUMENTS**

| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Foreign Patent Document                                                         | Publication<br>Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited<br>Document        | Pages, Columns, Lines<br>Where Relevant<br>Passages or Relevant<br>Figures Appear | T <sup>6</sup> |
|-----------------------|--------------------------|---------------------------------------------------------------------------------|-----------------------------------|--------------------------------------------------------------|-----------------------------------------------------------------------------------|----------------|
|                       |                          | Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known) |                                   |                                                              |                                                                                   |                |
|                       | 1                        | DE 101 00 052 A 1                                                               | 07-11-2002                        | Institut für<br>Medizintechnologie<br>Magdeburg GmbH         |                                                                                   |                |
|                       | 2                        | WO 91/08760                                                                     | 06-27-1991                        | Brigham and<br>Women's Hospital                              |                                                                                   |                |
|                       | 3                        | WO 95/04533                                                                     | 02-16-1995                        | Andrulis<br>Pharmaceuticals<br>Corporation                   |                                                                                   |                |
|                       | 4                        | WO 96/12737                                                                     | 05-02-1996                        | Immologic<br>Pharmaceutical<br>Corporation                   |                                                                                   |                |
|                       | 5                        | WO 01/54707 A2                                                                  | 08-02-2001                        | Meltec Multi-<br>Epitope-Ligand-<br>Technologies GmbH        |                                                                                   |                |
|                       | 6                        | WO 01/89569 A1                                                                  | 11-29-2001                        | Institut für<br>Medizintechnologie<br>Magdeburg GmbH<br>IMTM |                                                                                   |                |

|                       |                    |
|-----------------------|--------------------|
| Examiner<br>Signature | Date<br>Considered |
|-----------------------|--------------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign inside this box +

PTO/SB/08B(05/03)

Approved for use through 05/31/2003, OMB 0651-0031

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT***(Use as many sheets as necessary)*

|       |   |    |   |                    |            |
|-------|---|----|---|--------------------|------------|
| Sheet | 2 | of | 2 | Application Number | 10/520,014 |
|-------|---|----|---|--------------------|------------|

|                      |                 |
|----------------------|-----------------|
| Filing Date          | March 6, 2006   |
| First Named Inventor | Ansorge, et al. |
| Group Art Unit       |                 |
| Examiner Name        |                 |

|                        |              |
|------------------------|--------------|
| Attorney Docket Number | 013183.00044 |
|------------------------|--------------|

**NON PATENT LITERATURE DOCUMENTS**

| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate),<br>title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s),<br>volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|-----------------------|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
|                       | 1                        | ANSORGE, et al.; Dipeptidyl Peptidase IV/CD26 and Aminopeptidase N/CD13 in Regulation of the Immune Response; In: International Congress Series, 2001, 1218 (Cell-Surface Aminopeptidases: Basic and Clinical Aspects), pages 85-94.                                  |                |
|                       |                          |                                                                                                                                                                                                                                                                       |                |
|                       |                          |                                                                                                                                                                                                                                                                       |                |
|                       |                          |                                                                                                                                                                                                                                                                       |                |
|                       |                          |                                                                                                                                                                                                                                                                       |                |
|                       |                          |                                                                                                                                                                                                                                                                       |                |
|                       |                          |                                                                                                                                                                                                                                                                       |                |
|                       |                          |                                                                                                                                                                                                                                                                       |                |
|                       |                          |                                                                                                                                                                                                                                                                       |                |
|                       |                          |                                                                                                                                                                                                                                                                       |                |

|                       |  |                    |  |
|-----------------------|--|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|--|--------------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Translation is attached.

Burden Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.